Cargando…

Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals

Determination of dynamic binding capacity (DBC) for capture purification chromatographic step is usually the first experiment to be performed during downstream process development of biopharmaceuticals. In this work, we investigated the application of inline variable pathlength technology using Flow...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhangale, Rashmi P., Ye, Rui, Lindsey, Thomas B., Wolfe, Leslie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285919/
https://www.ncbi.nlm.nih.gov/pubmed/35064963
http://dx.doi.org/10.1002/btpr.3236
_version_ 1784747891958480896
author Bhangale, Rashmi P.
Ye, Rui
Lindsey, Thomas B.
Wolfe, Leslie S.
author_facet Bhangale, Rashmi P.
Ye, Rui
Lindsey, Thomas B.
Wolfe, Leslie S.
author_sort Bhangale, Rashmi P.
collection PubMed
description Determination of dynamic binding capacity (DBC) for capture purification chromatographic step is usually the first experiment to be performed during downstream process development of biopharmaceuticals. In this work, we investigated the application of inline variable pathlength technology using FlowVPE for rapid determination of DBC on affinity resins for protein capture and proved its comparability with offline titer methods. This work also demonstrated that variable pathlength technology for DBC determination can be successfully applied to different classes of monoclonal antibodies and fusion proteins. This enabled rapid screening of affinity resins and optimization of the capture chromatography step. Hence, use of inline variable pathlength technology eliminated the dependency on offline titer data, traditionally used for DBC determination and accelerated overall process development timelines with less cost.
format Online
Article
Text
id pubmed-9285919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-92859192022-07-19 Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals Bhangale, Rashmi P. Ye, Rui Lindsey, Thomas B. Wolfe, Leslie S. Biotechnol Prog RESEARCH ARTICLES Determination of dynamic binding capacity (DBC) for capture purification chromatographic step is usually the first experiment to be performed during downstream process development of biopharmaceuticals. In this work, we investigated the application of inline variable pathlength technology using FlowVPE for rapid determination of DBC on affinity resins for protein capture and proved its comparability with offline titer methods. This work also demonstrated that variable pathlength technology for DBC determination can be successfully applied to different classes of monoclonal antibodies and fusion proteins. This enabled rapid screening of affinity resins and optimization of the capture chromatography step. Hence, use of inline variable pathlength technology eliminated the dependency on offline titer data, traditionally used for DBC determination and accelerated overall process development timelines with less cost. John Wiley & Sons, Inc. 2022-02-02 2022 /pmc/articles/PMC9285919/ /pubmed/35064963 http://dx.doi.org/10.1002/btpr.3236 Text en © 2022 KBI Biopharma. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle RESEARCH ARTICLES
Bhangale, Rashmi P.
Ye, Rui
Lindsey, Thomas B.
Wolfe, Leslie S.
Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title_full Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title_fullStr Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title_full_unstemmed Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title_short Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
title_sort application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285919/
https://www.ncbi.nlm.nih.gov/pubmed/35064963
http://dx.doi.org/10.1002/btpr.3236
work_keys_str_mv AT bhangalerashmip applicationofinlinevariablepathlengthtechnologyforrapiddeterminationofdynamicbindingcapacityindownstreamprocessdevelopmentofbiopharmaceuticals
AT yerui applicationofinlinevariablepathlengthtechnologyforrapiddeterminationofdynamicbindingcapacityindownstreamprocessdevelopmentofbiopharmaceuticals
AT lindseythomasb applicationofinlinevariablepathlengthtechnologyforrapiddeterminationofdynamicbindingcapacityindownstreamprocessdevelopmentofbiopharmaceuticals
AT wolfeleslies applicationofinlinevariablepathlengthtechnologyforrapiddeterminationofdynamicbindingcapacityindownstreamprocessdevelopmentofbiopharmaceuticals